omega-n-methylarginine has been researched along with losartan potassium in 7 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noris, M; Remuzzi, G | 1 |
| Imagawa, S | 1 |
| Higuchi, M; Imagawa, S; Imai, N; Nagai, T; Ohmine, K; Ozawa, K; Suzuki, N; Tarumoto, T; Yamamoto, M | 1 |
| Hasegawa, Y; Higuchi, M; Imagawa, S; Mukai, HY; Nagasawa, T; Neichi, T; Ozawa, K; Suzuki, N; Tarumoto, T; Yamamoto, M | 1 |
| Imagawa, S; Mukai, HY; Nagasawa, T; Obara, N; Ohmine, K; Ozawa, K; Suzuki, N; Yamamoto, M | 1 |
| Doi, T; Imagawa, S; Kodama, T; Nagasawa, T; Nakano, Y; Obara, N; Suzuki, N; Yamamoto, M | 1 |
| Buchspies, D; Fink, L; Gassmann, M; Ghofrani, HA; Grimminger, F; Keller, S; Manz, D; Mehling, T; Quanz, K; Schermuly, RT; Seeger, W; Voswinckel, R; Weissmann, N | 1 |
2 review(s) available for omega-n-methylarginine and losartan potassium
| Article | Year |
|---|---|
Uremic bleeding: closing the circle after 30 years of controversies?
Topics: Anemia; Animals; Arginine; Bleeding Time; Blood Platelets; Endothelium, Vascular; Enzyme Inhibitors; Erythropoietin; Guanidines; Hemorrhage; History, 18th Century; History, 20th Century; Humans; Isoenzymes; Kidney Failure, Chronic; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; omega-N-Methylarginine; Rats; Succinates; Uremia | 1999 |
[Erythropoietin and hypoxia responsive system].
Topics: Anemia; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; DNA-Binding Proteins; Erythropoietin; Event-Related Potentials, P300; Gene Expression Regulation; Genetic Therapy; Hepatocyte Nuclear Factor 4; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Failure, Chronic; Nuclear Proteins; omega-N-Methylarginine; Phosphoproteins; Transcription Factors; Transcription, Genetic | 1999 |
5 other study(ies) available for omega-n-methylarginine and losartan potassium
| Article | Year |
|---|---|
N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2.
Topics: Animals; Base Sequence; Binding Sites; Cyclic GMP; DNA; DNA-Binding Proteins; Enzyme Inhibitors; Erythropoietin; GATA2 Transcription Factor; Gene Expression Regulation; Humans; Hypoxia; Luciferases; Mice; Molecular Sequence Data; Mutation; NG-Nitroarginine Methyl Ester; Nitric Oxide; omega-N-Methylarginine; Promoter Regions, Genetic; Protein Binding; Recombinant Fusion Proteins; Transcription Factors; Tumor Cells, Cultured | 2000 |
L-arginine rescues decreased erythropoietin gene expression by stimulating GATA-2 with L-NMMA.
Topics: Anemia; Animals; Arginine; Cell Hypoxia; Cells, Cultured; Cyclic GMP; DNA-Binding Proteins; Enzyme Inhibitors; Erythropoietin; GATA2 Transcription Factor; Gene Expression; Humans; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; omega-N-Methylarginine; Oxygen; Promoter Regions, Genetic; RNA, Messenger; Transcription Factors; Uremia | 2002 |
GATA suppresses erythropoietin gene expression through GATA site in mouse erythropoietin gene promoter.
Topics: Animals; Arginine; Binding Sites; Catalase; DNA-Binding Proteins; Down-Regulation; Erythroid-Specific DNA-Binding Factors; Erythropoietin; GATA2 Transcription Factor; GATA3 Transcription Factor; Hydrogen Peroxide; Mice; omega-N-Methylarginine; Promoter Regions, Genetic; Trans-Activators; Transcription Factors; Transfection; Tumor Cells, Cultured | 2002 |
A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA.
Topics: Anemia; Animals; Anisoles; Azepines; Binding Sites; Cell Count; Cell Hypoxia; Cell Line; DNA-Binding Proteins; Erythropoietin; Hemoglobins; Interleukin-1; Mice; Models, Genetic; omega-N-Methylarginine; Promoter Regions, Genetic; Reticulocytes; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2003 |
Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Blood Pressure; Blood Vessels; Blood Viscosity; Cyclooxygenase Inhibitors; Erythropoietin; Hematocrit; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Hypoxia; Lung; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Nitric Oxide Synthase; omega-N-Methylarginine; Up-Regulation; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2005 |